Alirocumab

Alirocumab has been studied in 58 papers since 2017: 9 trials and 24 observational studies in people, 1 in animals, 20 reviews; 49 in the past year. It is an approved medicine. The newest story, Nov 9, 2026: “Weighted blood marker better predicted heart and stroke risk”.

InterventionApproved 2015

58 papers study it35 findingsUpdated

MeSH

33 new papers in 30 daysSee all 58 papers on alirocumab

At a glance

Alirocumab lowers cardiovascular events and LDL cholesterol in humans, replicated by independent labs; a trial reports fewer deaths at age 65 or older. An observational comparison of monthly versus biweekly dosing finds no clear cardiovascular-event link. Papers declare developer ties; aging-related trials are registered, while most trials across uses are developer-sponsored and some ended over a year ago without posted results.

35 findings in 22 papers from 2019 to 2026, 13 of them since August 2026

Independent labs found the same change in people. 16 independent labs in 12 countries; 66 trials, 12 about aging, 10 with no results posted.

“Across BMI categories, alirocumab hazard ratios for MACE were 0.98, 0.85, 0.80, and 0.74 (trend interaction p=0.071).”
Body Mass Index, LDL-Cholesterol Response, and Cardiovascular Outcomes with Alirocumab After Acute Coronary SyndromeAHA Scientific Sessions 2026 abstract2026doi:10.1161/circ.154.suppl_1.6938

2 of its findings point the other way.

Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
  • 16 independent labs in 12 countries
  • 2 findings against
  • 66 trials, 12 about aging, 10 with no results posted
  • Funders: Hunan University and others
  • 14 of 32 findings with company ties
  • 45 of 66 trials sponsored by its developers
  • Human trial9
  • Humans24
  • Animals1
  • In silico1

6 studies gave alirocumab to people and measured what changed.

What changedDesignPeopleSource

down: Decreases CERT2Approximately 2 risk-score points lower than placebo

Treated cohort4 months4,285 peoplePatient cohortsAHA Scientific Sessions 2026 abstract, Nov 2, 2026

down: Decreases LDL cholesterol

Randomized trial52 weeks125 peopleBoth59 (51; 64) yearsPatients with acute coronary syndrome not achieving LDL-cholesterol target with statin therapyJournal of clinical medicine, Sep 29, 2026

up: Increases carotid plaque regressionregression proportions exceeded 30%

down: Decreases intraplaque neovascularization

down: Decreases LDL-C

Randomized trial12 months299 peoplePatients with high CVD risk with non-calcified plaque on the carotid arteryFrontiers in pharmacology, Aug 27, 2026

down: Decreases LDL cholesterol-34.1%

Trial1 month26 peopleAfter acute coronary syndrome, switched from inclisiranTerapevticheskii arkhiv, Mar 7, 2026

down: Decreases ceramide

Randomized trial265 peopleIn patients with acute myocardial infarctionCirculation. Genomic and precision medicine, Feb 10, 2026

What did studies of alirocumab find?

17

Studies of alirocumab measured 17 outcomes; the most studied are LDL cholesterol (7 studies), major adverse cardiovascular events (2) and lipoprotein (2).

LDL cholesterol

downin humans7−34%

7 studies
  1. Alirocumab decreases LDL cholesterol in humans.

    “Between-group comparison of LDL-C changes revealed a statistically significant difference (p < 0.001), with a more pronounced reduction in LDL-C in the Alirocumab group.”

    Human trial52 weeksn = 61

    Ezetimibe Versus Alirocumab and Plaque Vulnerability in Patients with Acute Coronary Syndrome Not Achieving LDL-Cholesterol Target with Statin Therapy: The COMBI-LLT-ACS Randomized Trial

    Journal of clinical medicine

  2. Alirocumab decreases LDL cholesterol in humans after acute coronary syndrome, switched from inclisiran (-34.1%).

    “The first administration of alirocumab at visit 3 was associated with the greatest reduction in LDL-C over the month (-34.1%; p = 0.001).”

    Human trialafter acute coronary syndrome, switched from inclisiran1 monthn = 26

    Dynamics of lipid metabolism parameters following the change of targeted therapy for hypercholesterolemia after acute coronary syndrome

    Terapevticheskii arkhiv

  3. Alirocumab is linked with lower LDL cholesterol in humans (−58.2% (−1.98 mmol/L), unadjusted).

    “mean unadjusted LDL-C reductions were − 58.2% (–1.98 mmol/L), − 58.9% (–2.09 mmol/L), and − 33.2% (–1.17 mmol/L), respectively (p < 0.001).”

    Humansn = 598

    Real-world effectiveness and cardiovascular outcomes of PCSK9 inhibitor therapy: a prospective registry study

    Lipids in health and disease

  4. Alirocumab is linked with lower LDL cholesterol in humans (add-on to ezetimibe, statin contraindicated) (82% lower (from 6.6 to 1.2 mmol/L)).

    “LDLc was 82% lower as compared to baseline values (from 6.6 to 1.2 mmol/L).”

    Humansadd-on to ezetimibe, statin contraindicated24 monthsmales

    Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report

    Frontiers in medicine

  5. Alirocumab decreases LDL cholesterol in humans.

    “The monoclonal antibodies evolocumab and alirocumab substantially reduce LDL-C levels and cardiovascular risk”

    Review

    PCSK9 Inhibition in Transition: From Established Treatments to Emerging Therapeutic Approaches

    International journal of molecular sciences

  6. Alirocumab decreases LDL cholesterol in humans (chronic kidney disease).

    “Evolocumab, alirocumab, and inclisiran consistently lowered low-density lipoprotein cholesterol”

    Reviewchronic kidney disease

    PCSK9-Targeted Therapy and Kidney Function in Chronic Kidney Disease: A Systematic Review and Narrative Synthesis

    Clinical therapeutics

  7. Alirocumab decreases LDL cholesterol in humans (50%-60% reduction).

    “Monoclonal antibodies (alirocumab, evolocumab) and siRNA (inclisiran) consistently reduce LDL-C by 50%-60%.”

    Review

    Proprotein Convertase Subtilisin/Kexin Type 9: From Biology to Therapeutic Targeting in Cardiovascular Disease

    European journal of clinical investigation

More on LDL cholesterol

Major adverse cardiovascular events

no changein humans1downin humans1HR 0.78

2 studies
  1. Alirocumab decreases major adverse cardiovascular events in humans (patients aged ≥65 years; consistent with <65 years) (HR 0.78 (0.68-0.91) for ≥65 years).

    “Relative risk reductions were consistent for patients ≥65 vs. <65 years for MACE [hazard ratio (HR) 0.78, 95% confidence interval (CI) 0.68-0.91 vs. 0.89, 0.80-1.00; Pinteraction = 0.19]”

    Human trialpatients aged ≥65 years; consistent with <65 years

    Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis

    European heart journal

  2. Alirocumab was not clearly linked with major adverse cardiovascular events in humans (Hong Kong patients prescribed alirocumab) (Biweekly 8.6% versus monthly 8.9%; p=0.829).

    “At 12 months, there was no statistically significant difference in the incidence of MACE between groups (8.6% vs. 8.9%; p=0.829).”

    HumansHong Kong patients prescribed alirocumabmonthly versus biweekly12 monthsn = 2,012

    Real-world outcomes of biweekly and monthly alirocumab regimens: a population-based analysis

    ESC Congress 2026 abstract

Lipoprotein

downin humans2

2 studies
  1. Alirocumab decreases lipoprotein in humans (recent acute coronary syndromes) (mean 25% reduction in time-weighted Lp(a)).

    “Alirocumab reduced time-weighted Lp(a) by a mean 25%.”

    Human trialrecent acute coronary syndromes

    Association of lipoprotein(a) levels with risk of serious bleeding : findings from the ODYSSEY OUTCOMES trial

    ESC Congress 2026 abstract

  2. Alirocumab decreases lipoprotein in humans (meta-analyses of RCTs) (18.55-26.46%).

    “alirocumab (18.55-26.46%; high certainty), and inclisiran (18.00%; high certainty).”

    Reviewmeta-analyses of RCTs150 mg biweekly

    Effect of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Lipoprotein(a) Levels: An Umbrella Review of Meta-analyses of Randomized Controlled Trials

    Drugs

More on Lipoprotein

Carotid plaque regression

upin humans1

1 study
  1. Alirocumab increases carotid plaque regression in humans (added to atorvastatin, with or without ezetimibe) (p = 1.76e-07, CI 95% [0.09, 0.22]).

    “The highest proportions of plaque regression were observed in the Statin_P and Statin_EP groups”

    Human trialadded to atorvastatin, with or without ezetimibecarotid artery12 months

    Effects of different statin-based lipid-lowering therapies on stabilization and regression of carotid plaque: a randomized open-label trial

    Frontiers in pharmacology

  2. Alirocumab increases carotid plaque regression in humans (combination with statin) (regression proportions exceeded 30%).

    “Combination of lipid-lowering therapies with a PCSK9 inhibitor showed a greater effect on plaque regression.”

    Human trialcombination with statin12 monthsn = 299

    Effects of different statin-based lipid-lowering therapies on stabilization and regression of carotid plaque: a randomized open-label trial

    Frontiers in pharmacology

CERT2

downin humans1

1 study
  1. Alirocumab decreases CERT2 in humans (Approximately 2 risk-score points lower than placebo).

    “Alirocumab significantly reduced CERT2 by approximately 2 risk-score points compared with placebo at 4-month follow-up.”

    Human trialCompared with placebo, each added to optimized statin therapy after acute coronary syndrome4 months

    Ceramides, Cardiovascular Risk After Acute Coronary Syndrome, and the Effect of PCSK9 Inhibition with Alirocumab

    AHA Scientific Sessions 2026 abstract

More on CERT2

LDL cholesterol target attainment

no changein humans1

1 study
  1. Alirocumab was not clearly linked with LDL cholesterol target attainment in humans (acute coronary syndrome subgroup) (p>0.05).

    “In the ACS subgroup (n=404), both regimens demonstrated comparable rates of MACE and lipid control (all p>0.05).”

    Humansacute coronary syndrome subgroupmonthly versus biweekly12 monthsn = 404

    Real-world outcomes of biweekly and monthly alirocumab regimens: a population-based analysis

    ESC Congress 2026 abstract

Serious bleeding risk

downin humans1HR 0.81

1 study
  1. Alirocumab decreases serious bleeding risk in humans (versus placebo in patients with recent acute coronary syndromes) (HR 0.810 (95% CI 0.653–1.005), p=0.056; numerical reduction).

    “there were numerically fewer serious bleeding events with ALI than with placebo: HR (95% CI) = 0.810 (0.653, 1.005), p=0.056.”

    Human trialversus placebo in patients with recent acute coronary syndromesmedian 2.8 years

    Association of lipoprotein(a) levels with risk of serious bleeding : findings from the ODYSSEY OUTCOMES trial

    ESC Congress 2026 abstract

Intraplaque neovascularization

downin humans1

1 study
  1. Alirocumab decreases intraplaque neovascularization in humans (added to atorvastatin, with or without ezetimibe) (p = 0.02, CI 95% [0.00, 0.12]).

    “the IPN was prominently reduced in the Statin_P and Statin_EP groups”

    Human trialadded to atorvastatin, with or without ezetimibecarotid artery

    Effects of different statin-based lipid-lowering therapies on stabilization and regression of carotid plaque: a randomized open-label trial

    Frontiers in pharmacology

More on Intraplaque neovascularization

LDL-C

downin humans1

1 study
  1. Alirocumab decreases LDL-C in humans (added to atorvastatin, with or without ezetimibe; compared with groups without alirocumab).

    “At 6 months, the Statin_P and Statin_EP groups exhibited significantly lower LDL-C levels compared to the Statin and Statin_E groups (p < 0.05).”

    Human trialadded to atorvastatin, with or without ezetimibe; compared with groups without alirocumab6 months

    Effects of different statin-based lipid-lowering therapies on stabilization and regression of carotid plaque: a randomized open-label trial

    Frontiers in pharmacology

More on LDL-C

Intraplaque neovascularization

downin humans1

1 study
  1. Alirocumab decreases intraplaque neovascularization in humans (combination with statin).

    “The proportions of 0 grade IPN were higher in the Statin_P and Statin_EP groups after treatment.”

    Human trialcombination with statin12 monthsn = 299

    Effects of different statin-based lipid-lowering therapies on stabilization and regression of carotid plaque: a randomized open-label trial

    Frontiers in pharmacology

Ceramide

downin humans1

1 study
  1. Alirocumab decreases ceramide in patients with acute myocardial infarction.

    “Lipidomics identified more pronounced reductions in cholesteryl esters, ceramides, sphingomyelins, phosphatidylcholines, triglycerides, and diglycerides in PCSK9 mAb-treated patients with MI.”

    Human trialin patients with acute myocardial infarctionplasma

    Integrative Proteomic and Lipidomic Analysis of Patients With Acute Myocardial Infarction Treated With PCSK9 Antibodies and Statins

    Circulation. Genomic and precision medicine

More on Ceramide

APOB

downin humans1

1 study
  1. Alirocumab decreases APOB in patients with acute myocardial infarction receiving statins.

    “PCSK9 mAb therapy resulted in greater reductions in APOB (apolipoprotein B), APOE (apolipoprotein E), APOC2 (apolipoprotein C2), and APOC3 (apolipoprotein C3)”

    Human trialin patients with acute myocardial infarction receiving statinsplasma

    Integrative Proteomic and Lipidomic Analysis of Patients With Acute Myocardial Infarction Treated With PCSK9 Antibodies and Statins

    Circulation. Genomic and precision medicine

More on APOB

Adverse events

no changein humans1

1 study
  1. Alirocumab showed no clear effect on adverse events in humans (versus placebo, in older patients).

    “there were no differences between alirocumab and placebo”

    Human trialversus placebo, in older patients

    Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis

    European heart journal

All-cause death

downin humans1HR 0.77

1 study
  1. Alirocumab decreases all-cause death in humans (patients aged ≥65 years; not significant in <65 years) (HR 0.77 (0.62-0.95) for ≥65 years).

    “and all-cause death [HR 0.77, 0.62-0.95 vs. 0.94, 0.77-1.15; Pinteraction = 0.46]”

    Human trialpatients aged ≥65 years; not significant in <65 years

    Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis

    European heart journal

All 17

What is alirocumab linked with?

8

Studies link alirocumab with 8 measures, among them major adverse cardiovascular events, mortality and LDL cholesterol target attainment.

Major adverse cardiovascular events

downin humans2HR 0.98

2 studies
  1. Alirocumab lowers the risk of major adverse cardiovascular events in humans (HRs 0.98, 0.85, 0.80, and 0.74 across increasing BMI categories; trend interaction p=0.071).

    “Across BMI categories, alirocumab hazard ratios for MACE were 0.98, 0.85, 0.80, and 0.74 (trend interaction p=0.071).”

    Human trialversus placebo after acute coronary syndrome; BMI categories <25, 25–<30, 30–<35, and ≥35 kg/m275 mg with protocol-driven up-titration to 150 mgn = 18,924

    Body Mass Index, LDL-Cholesterol Response, and Cardiovascular Outcomes with Alirocumab After Acute Coronary Syndrome

    AHA Scientific Sessions 2026 abstract

  2. Alirocumab lowers the risk of major adverse cardiovascular events in humans (hypercholesterolemia; versus control) (OR 0.87, 95% CrI 0.80–0.95).

    “For MACE, evolocumab (OR 0.85, 95% CrI 0.79–0.92) and alirocumab (0.87, 0.80–0.95) significantly reduced cardiovascular events”

    Reviewhypercholesterolemia; versus control

    Comparative LDL-C Reduction and Cardiovascular Outcomes With PCSK9-Pathway Therapies: A Systemic Review and Network Meta-Analysis

    ESC Congress 2026 abstract

Mortality

upin humans1HR 1.358

1 study
  1. Alirocumab is associated with mortality in humans (Compared with evolocumab in patients with atherosclerotic heart disease and dyslipidemia) (3 years: HR 1.358 (95% CI 1.200–1.536); 5 years: HR 1.325 (1.193–1.470)).

    “mortality favored evolocumab at 3 years (HR 1.358, 95% CI 1.200-1.536) and 5 years (HR 1.325, 95% CI 1.193-1.470).”

    HumansCompared with evolocumab in patients with atherosclerotic heart disease and dyslipidemia3 and 5 years

    Comparative Cardiovascular Outcomes Across PCSK9-Targeted Therapies: A Real-World Matched Cohort Analysis of Inclisiran, Alirocumab, and Evolocumab

    AHA Scientific Sessions 2026 abstract

LDL cholesterol target attainment

upin humans1

1 study
  1. Alirocumab is associated with LDL cholesterol target attainment in humans (Hong Kong patients prescribed alirocumab) (<1.4 mmol/L: 64.8% versus 54.0%, p=<0.001; <1.8 mmol/L: 75.5% versus 66.2%, p=0.002; >50% reduction: 56.6% versus 48.0%, p=0.007).

    “higher proportions achieving LDL-C targets at all thresholds:”

    HumansHong Kong patients prescribed alirocumabmonthly versus biweekly12 monthsn = 2,012

    Real-world outcomes of biweekly and monthly alirocumab regimens: a population-based analysis

    ESC Congress 2026 abstract

Treatment persistence

upin humans1

1 study
  1. Alirocumab is associated with treatment persistence in humans (Hong Kong patients prescribed alirocumab) (83.7% versus 77.2%; p=0.001).

    “Monthly dosing was associated with superior treatment persistence (83.7% vs. 77.2%; p=0.001)”

    HumansHong Kong patients prescribed alirocumabmonthly versus biweekly12 monthsn = 2,012

    Real-world outcomes of biweekly and monthly alirocumab regimens: a population-based analysis

    ESC Congress 2026 abstract

Composite risk of all-cause death, myocardial infarction, or ischemic stroke

downin humans1

1 study
  1. Alirocumab is associated with composite risk of all-cause death, myocardial infarction, or ischemic stroke in humans (Observed ARR 6.0% (95% CI 3.0–9.0%); RRR 38.7% (18.7–58.7%); g-computation ARR 5.9% (3.3–8.2%), RRR 38.6% (21.0–50.7%); all p<0.001).

    “alirocumab was associated with lower 4-year risk of all-cause death, MI, or ischemic stroke”

    HumansEstablished atherosclerotic cardiovascular disease without prior myocardial infarction, unstable angina, or ischemic stroke; compared with no PCSK9 inhibitor75 mg Q2W, 150 mg Q2W, or 300 mg Q4W4 years62% male among alirocumab users; 63% among comparatorssn = 4,008

    Alirocumab and cardiovascular outcomes in patients without a prior ischemic event

    ESC Congress 2026 abstract

Rehospitalization for any and cardiovascular reasons

downin humans1

1 study
  1. Alirocumab is associated with rehospitalization for any and cardiovascular reasons in humans (More than three-fold decrease).

    “A more than three-fold decrease in the need for rehospitalizations for any and cardiovascular reasons was noted among patients with an earlier start of PCSK9-targeted therapy.”

    HumansEarlier versus later initiation after ACS, as part of multicomponent lipid-lowering therapy18 months after ACS

    Time to achieve target lipid metabolism parameters and its impact on long-term outcomes after acute coronary syndrome in conditions of multicomponent lipid-lowering therapy

    Terapevticheskii arkhiv

Target LDL cholesterol attainment

upin humans1

1 study
  1. Alirocumab is associated with target LDL cholesterol attainment in humans (Earlier versus later initiation: 83.3% versus 40.0% at 6 months; 88.9% versus 55.0% at 12 months).

    “the proportions of those who achieved the target low-density lipoprotein cholesterol after 6 and 12 months, respectively, were 40.0 and 83.3% (p=0.008), 55.0 and 88.9% (p=0.024).”

    HumansAlirocumab initiation within 3 months versus 3 or more months after ACS, as part of multicomponent lipid-lowering therapy6 and 12 months after ACS

    Time to achieve target lipid metabolism parameters and its impact on long-term outcomes after acute coronary syndrome in conditions of multicomponent lipid-lowering therapy

    Terapevticheskii arkhiv

More on Target LDL cholesterol attainment

Musculoskeletal and connective tissue disorders

upin humans1

1 study
  1. Alirocumab is linked with a higher risk of musculoskeletal and connective tissue disorders in humans (compared with all other drugs in FAERS) (ROR1 = 2.626, 95% CI 2.552-2.702).

    “both alirocumab and evolocumab had a significant signal in "musculoskeletal and connective tissue disorders"”

    Humanscompared with all other drugs in FAERS

    Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS

    Frontiers in pharmacology

Has alirocumab been tested in people?

12 of 66 about aging

Yes: 9 trials and 24 observational studies in people have been published, and 60 trials are registered.

Approved

  • FDA Praluent

    Jul 24, 2015Homozygous Familial Hypercholesterolemia, Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia

  • EMA Praluent

    Sep 23, 2015Dyslipidemias, Atherosclerotic Cardiovascular Disease, Hypercholesterolaemia

Repurposing

All 25

Every condition in trials

  • Hyperlipidemias

    Phase 4Results posted3 trials

  • Hyperlipoproteinemia type II

    Phase 4Completed1 trial

  • Non familial hypercholesterolemia

    Phase 4Terminated1 trial

  • TYPE2 diabetes

    Phase 3Completed1 trial

  • Pharmacodynamic

    Phase 1Results posted1 trial

  • Pharmacokinetic

    Phase 1Results posted1 trial

Stopped

  • NCT03694197TerminatedHeterozygous familial hypercholesterolemia

    The primary objective (to evaluate the long-term safety of Praluent) was adequately evaluated in other studies.

  • NCT03004001TerminatedNephrotic syndrome

    Difficult recruitment

Who is developing alirocumab?

1 company: Regeneron Pharmaceuticals.

Companies
  • Regeneron PharmaceuticalsPhase 2hypercholesterolemia

Trial sponsors

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Alirocumab reduces cardiovascular events and mortality in adults aged 65 or older in a human trial; independent labs also report fewer cardiovascular events in humans. A cohort finds no clear cardiovascular-event difference between monthly and biweekly dosing. Most registered trials across uses are sponsored by Sanofi or Regeneron; some ended over a year ago without posted results.

  2. Summary rewritten as its findings changed.

    As it read before

    A human trial of alirocumab reports carotid plaque regression at 12 months and reduced intraplaque neovascularization and LDL-C at six months; a review describes fewer major adverse cardiovascular events. Direct findings come from one lab. Regeneron and Sanofi sponsor 41 of 58 registered trials; 12 trials ended over a year ago without posted results or papers citing them.

  3. Summary written from the findings.

Latest

Dec 2025: 0Jan 2026: 2Feb 2026: 5Mar 2026: 2Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 1Aug 2026: 2Sep 2026: 3Oct 2026: 12Nov 2026: 2249 papers in 12 months
AHA Scientific Sessions 2026 Abstract

Weighted blood marker better predicted heart and stroke risk

Absolute reductions in the risk of heart and stroke events with alirocumab versus placebo ranged from 0.5 to 4 percentage points across the marker’s range.Absolute reductions in the risk of heart and stroke events with alirocumab versus placebo ranged from 0.5 to 4 percentage points across the marker’s range.

Randomized trial · 11,957 peopleBiomarkers
AHA Scientific Sessions 2026 Abstract

Evolocumab linked to fewer deaths in high-risk adults

Over three years, deaths occurred in 1.4% of evolocumab users versus 2.7% of alirocumab users across 2,610 matched pairs.Over three years, deaths occurred in 1.4% of evolocumab users versus 2.7% of alirocumab users across 2,610 matched pairs.

Cohort studyEvolocumab

See all 58 papers on alirocumab